Intranasal Delivery of Drugs for Ischemic Stroke Treatment: Targeting IL-17A
Stroke is the second most common cause of death worldwide and a major cause of disability. However, uncertainty surrounds the efficacy and safety of peripheral or intracerebroventricular drug administration for stroke treatment. Intranasal delivery is emerging as a noninvasive option for delivering drugs to the central nervous system with minimal peripheral exposure. Use of the intranasal route could potentially reduce systemic exposure and side effects. Intranasal delivery provides rapid onset that occurs within minutes. Additionally, this method facilitates the delivery of large and/or charged molecules, which fail to effectively cross the blood-brain barrier. We have shown previously that intranasal delivery of exogenous interleukin-17A (IL-17A) promotes the survival, neuronal differentiation, and subsequent synaptogenesis of neural precursor cells in the subventricular zone during stroke recovery, as well as spontaneous recovery and angiogenesis. Therefore, although IL-17A is well-known for contributing to damage in acute ischemic stroke, it might also mediate neurorepair and spontaneous recovery after stroke when delivered intranasally.
KeywordsCentral nervous system Interleukin-17 A Intranasal delivery Neurorepair Stroke
- 2.Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart disease and stroke statistics—2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–e292.CrossRefGoogle Scholar
- 3.Schwamm LH, Ali SF, Reeves MJ, Smith EE, Saver JL, Messe S, Bhatt DL, Grau-Sepulveda MV, Peterson ED, Fonarow GC. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at get with the guidelines-stroke hospitals. Circ Cardiovasc Qual Outcomes. 2013;6:543–9.CrossRefGoogle Scholar
- 8.Frey WH 2nd. (WO/1991/007947) neurologic agents for nasal administration to the brain (priority date 5.12.89). Geneva: World Intellectual Property Organization; 1991.Google Scholar
- 24.Gelderblom M, Weymar A, Bernreuther C, Velden J, Arunachalam P, Steinbach K, Orthey E, Arumugam TV, Leypoldt F, Simova O, Thom V, Friese MA, Prinz I, Holscher C, Glatzel M, Korn T, Gerloff C, Tolosa E, Magnus T. Neutralization of the IL-17 axis diminishes neutrophil invasion and protects from ischemic stroke. Blood. 2012;120:3793–802.CrossRefGoogle Scholar
- 40.Hu MH, Zheng QF, Jia XZ, Li Y, Dong YC, Wang CY, Lin QY, Zhang FY, Zhao RB, Xu HW, Zhou JH, Yuan HP, Zhang WH, Ren H. Neuroprotection effect of interleukin (IL)-17 secreted by reactive astrocytes is emerged from a high-level IL-17-containing environment during acute neuroinflammation. Clin Exp Immunol. 2014;175:268–84.CrossRefGoogle Scholar